SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs that treat diabetes by increasing urinary glucose excretion to lower blood glucose concentration, have manifested benefits in other diseases recently.